Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy
Open accessPublished version of a preprint
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index; 15 of the 29 sources its claims cite were checked for support.
Abstract
SagA promotes immunotherapy response: The gut microbiome can influence the treatment outcome for cancer patients receiving PD-L1 immunotherapy, but the mechanisms underlying favorable responses are unclear. Griffin et al . found that a particular type of bacteria called enterococci enhance anti–PD-L1 immunotherapy in mice (see the Perspective by Ansaldo and Belkaid). The researchers show that enterococci secrete an enzyme called SagA that breaks down components of the bacterial cell wall. This process results in the release of muramyl peptide fragments, which in turn act as stimulatory molecules to promote signaling of the innate immune sensor protein NOD2 and improved immunotherapy responses. —PNK
Overview
CoChat Summary
TL;DR
Enterococcus species that produce secreted NlpC/p60 peptidoglycan hydrolases (SagA orthologs) improve checkpoint inhibitor responses in mouse tumor models by generating NOD2-active muropeptides. Engineering SagA into non-active E. faecalis or probiotic L. lactis, or giving synthetic MDP-l,d, reproduced antitumor benefit with anti-PD-L1.
Key findings
- In antibiotic-pretreated C57BL/6 mice bearing B16-F10 melanoma, oral E. faecium Com15 plus anti-PD-L1 reduced tumor size at high and low antibody doses versus anti-PD-L1 alone; all three E. faecium isolates tested were active, while no E. faecalis strain was. Similar fecal CFU across strains indicated the effect was not due to bacterial load.
- Active species E. durans, E. hirae, and E. mundtii shared peptidoglycan remodeling signatures and SagA orthologs; C-terminal NlpC/p60 domains were >90% identical, E. gallinarum’s closest protein was 67% identical, and E. faecalis lacked direct orthologs. Recombinant orthologs showed d,l-endopeptidase activity producing GMDP.
- E. faecalis engineered to express SagA plus anti-PD-L1 reduced B16-F10 growth, and this required NOD2. L. lactis expressing wild-type SagA matched E. faecium benefit, whereas catalytically inactive C443A SagA did not.
- Synthetic NOD2-active MDP-l,d with anti-PD-L1 significantly inhibited tumors, unlike MDP-l,l; scRNA-seq showed more intratumoral T lymphocytes, cytotoxic gene enrichment, a Cx3cr1/Nr4a1 monocyte increase, and NF-κB/inflammatory signatures.
Methods
- Mouse tumor models: SPF C57BL/6 mice (Jackson) pretreated two weeks with ampicillin, colistin, and streptomycin, then orally supplemented with enterococci, implanted with B16-F10 melanoma and treated with anti-PD-L1; separate Taconic SPF mice without antibiotics; MCA205 fibrosarcoma with anti-PD-1 and MC38 colorectal carcinoma with anti-CTLA-4; B16-OVA for flow cytometry.
- Bacterial and biochemical assays: HPLC-MS peptidoglycan fragment profiling, genomic/sequence alignments for SagA orthologs, Western blot for secretion, recombinant hydrolase activity assays, fecal/tissue CFU, and 16S rRNA microbiome analysis.
- Immune profiling: tumor-infiltrating lymphocytes quantified by flow cytometry; CD45+ tumor cells from MDP stereoisomer-treated mice analyzed by scRNA-seq and gene set enrichment.
Limitations
- Stated: the authors could not detect SagA orthologs in clinical metagenomic datasets before checkpoint blockade, which they attribute to low E. faecium genome coverage (9.34%). They also note uncertainty for the secretion-deficient L. lactis SagA strain, suggesting either low secreted SagA was sufficient or non-secreted SagA leaked via lysis.
- Evident: efficacy and mechanism data come from mouse tumor models and bacterial/muropeptide interventions, not human clinical trials; antibiotic pretreatment substantially depletes resident microbiota, although a non-antibiotic SPF model was also used.
- Evident: microbiome analyses showed incomplete antibiotic clearance and shifts over time, and some differential OTUs appeared in only one cage per condition, limiting microbiome attribution.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 0 Not valid · 7 Not checked · 63 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Multiple analyses of the commensal microbiome from human cohorts treated with immunotherapies targeting PD-1 have revealed that the bacterial genus Enterococcus is enriched in responding patients (12, 13).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Not checked yetcites [12] Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria J-C, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L, Gut microbiome influences efficacy of PD-1–ba source
- Partly supportedcites [13] Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF, The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
In the paper’s results (our copy labels the section Abstract; page unavailable), Enterococcus faecium is listed among species more abundant in responders. The paper reports enrichment of that species in a metastatic melanoma cohort, not enrichment of the genus Enterococcus as a whole across human cohorts. (LLM, conf=0.83)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, the gut microbiota has emerged as a potent new factor associated with the efficacy of anti–CTLA4, anti–PD-1, and anti–PD-L1 treatment (8-14).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Partly supportedcites [8] Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CPM, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther P-L, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L, Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 350, 1079– 1084 (2015). 26541610 PMC4721659 sourceExperimental — accuracy not yet measured
The Abstract reports that gut microbiota composition influences the efficacy of CTLA-4 blockade, supporting the anti-CTLA-4 part of the sentence. The passages in our copy do not establish the same association for anti-PD-1 or anti-PD-L1 treatment, so this source does not support the full three-treatment claim. (LLM, conf=0.88)
- Partly supportedcites [9] Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre M-L, Chang EB, Gajewski TF, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 350, 1084– 1089 (2015). 26541606 PMC4873287 sourceExperimental — accuracy not yet measured
The supplied passages report that gut microbial composition influenced response to anti–PD-L1 treatment in mice. They discuss effects on the PD-1/PD-L1 axis more broadly, but do not report a direct anti–PD-1 treatment test; the CTLA-4 passage says the principles *could* apply to that pathway. Thus this source supports the anti–PD-L1 part, but not the claim that microbiota is established as associated with efficacy for all three treatments. (LLM, conf=0.88)
- Supportedcites [10] Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, Koh AY, Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia. 19, 848– 855 (2017). 28923537 PMC5602478 source
The Introduction reports that gut microbiota influence responses to anti-PD-L1 and anti-CTLA4 therapy in mouse models. The Discussion reports gut microbial species associated with clinical response to anti-PD1 alone and combined anti-PD1/anti-CTLA4 therapy in melanoma patients. Together, these passages support the broad association claimed; page numbers are not provided in our copy. (LLM, conf=0.92)
- Supportedcites [11] Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza I source
The paper reports an association between gut microbiome composition and anti-PD-1 response in melanoma patients, cites a similar finding in a small anti-CTLA-4 cohort, and reports improved anti-PD-L1 response in mice receiving fecal transplants from anti-PD-1 responders. These passages support the broad association claimed, although the evidence comes from different populations and study designs. (LLM, conf=0.87)
- Not checked yetcites [12] Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria J-C, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L, Gut microbiome influences efficacy of PD-1–ba source
- Partly supportedcites [13] Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF, The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
The paper reports an association between gut microbiota and anti–PD-1 response in metastatic melanoma patients, and its mouse experiments show differing anti–PD-L1 efficacy by microbiota (Abstract; Fig. 3F discussion; page unavailable). It included four anti–CTLA-4 recipients but reports no separate microbiota–efficacy association for that treatment. The anti–PD-L1 result is in mice, not patients. (LLM, conf=0.88)
- Supportedcites [14] Peters BA, Wilson M, Moran U, Pavlick A, Izsak A, Wechter T, Weber JS, Osman I, Ahn J, Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome Med. 11, 61 (2019). 31597568 PMC6785875 source
The Background reports gut-microbiota effects on anti-CTLA-4 and anti-PD-L1 immunotherapy in mice and an association with clinical response in human melanoma patients. The Discussion describes associations with response to anti-PD-1 and anti-CTLA-4 treatment in melanoma patients. Together, these passages support the broad association attributed to this source. (LLM, conf=0.90)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“consistent with enhanced priming of a tumor antigen-specific immune response (9, 13).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Supportedcites [9] Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre M-L, Chang EB, Gajewski TF, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 350, 1084– 1089 (2015). 26541606 PMC4873287 source
The paper reports greater expansion of tumor-antigen-specific CD8+ T cells in tumor-draining lymph nodes and describes differences in T-cell priming in vivo (passages [1] and [2], page unavailable). This supports the cited interpretation that an increase in antigen-specific CD8+ T cells is consistent with enhanced priming. The paper studied SIY-specific cells; the citing paper’s OVA-specific observation is not itself attributed to this source. (LLM, conf=0.88)
- Supportedcites [13] Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF, The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 359, 104– 108 (2018). 29302014 PMC6707353 source
The passage describing the mouse tumor experiment reports more SIY-specific CD8+ T cells and explicitly interprets this as increased priming of tumor antigen-specific CD8+ T cells. The citation is attached to that interpretation, not to the citing study’s OVA-specific measurement. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Significant enrichment of hallmark gene sets (33) for inflammatory response and NF-κB signaling were found in the MDP-l,d dataset (Table S8).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Supportedcites [33] Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P, The molecular signatures database hallmark gene set collection. Cell Syst. 1, 417– 425 (2015). 26771021 PMC4707969 source
The citation (33) is attached to 'hallmark gene sets' — an identification of the resource the citing authors ran enrichment against — not to their own MDP-l,d result. Our copy is exactly that source: the DISCUSSION states the hallmarks are released as the H Collection in MSigDB v5.0, every set name starting with HALLMARK, with Table 1 listing all 50 hallmarks and their descriptions; the RESULTS (Analysis of necrosis in glioblastoma) treat NFκB signaling as one of the biological themes covered, and the protein-phenotype validation section documents the immune/inflammatory hallmarks (IL6 JAK STAT3, IL2 STAT5 signaling). No passage of our copy reports anything about an 'MDP-l,d' dataset, which is consistent with that being the citing authors' own analysis rather than something attributed here. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We further confirmed that SagA orthologs are found in humans through alignment of the SagA NlpC/p60 domain with genomes within the Human Microbiome Project (24) (Fig. 2C, Table S5).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Supportedcites [24] Consortium THMJRS, A catalog of reference genomes from the human microbiome. Science. 328, 994– 999 (2010). 20489017 PMC2940224 source
The citation identifies the Human Microbiome Project genomes used for the citing authors’ alignment; the SagA result is presented as the citing authors’ own finding. The source’s Reference genome progress section describes the HMP-sequenced genomes, and its Data release section says their sequences and annotations were made available. (LLM, conf=0.91)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
54 more claims
Create a free account to see all 78 claims and to verify the 14 references still open.
- Probably not a substantial claim. 6
- It may state two separate claims as one. 14
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fourth, cause-effect relationships between the prevalence or relative abundance of particular taxa, and clinical regression or progression, have been shown in animal models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several probiotics or their products can inhibit tumor development by suppressing inflammation and promoting anti-tumor immune responses6,7.”
From Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Enterococcus expressed and secreted orthologs NlpC/p60 PG hydrolase SagA and could promote expression of the innate immune sensor protein nucleotide-binding oligomerization domain containing 2 (NOD2) and augment ICI antitumor efficacy [109] (Fig. 5F).”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [109]
In the citing paper
“Thus, the peptidoglycan hydrolase SagA from Enterococcus faecium can be transferred into Lactococcus lactis to generate a probiotic strain that stimulates innate immune responses via NOD2 activation and promotes ICI antitumor activity in mice.26”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [26]
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
IQ-TREE: A Fast and Effective Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies
Nguyen, L.-T., Schmidt, H. A., von Haeseler, A., & Minh, B. Q. (2015) · Molecular Biology and Evolution · doi:10.1093/molbev/msu300 · Cited by 26,046
phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data
McMurdie, P. J., & Holmes, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061217 · Cited by 21,322
Search and clustering orders of magnitude faster than BLAST
Edgar, R. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq461 · Cited by 20,826
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments
Price, M. N., Dehal, P. S., & Arkin, A. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009490 · Cited by 14,894
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Cited by
Items 201–300 of 367
Xian, Y., Chen, Z., Lan, Z., Zhang, C., Sun, H., Liu, Z., Kong, P., Liang, Y., Zhao, Y., Liu, S. M., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2557978 · Cited by 12
“18 Furthermore, we validated the augmenting effect of MNC-168 on anti-PD-1 therapy across multiple preclinical cancer models, reinforcing its translational potential.”
InfluentialRole of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer
Shi, L., Xu, Y., & Feng, M. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07689-0 · Cited by 9
Feng, H., Zhao, Y., Li, Y., Qi, X., Shen, S., & Zhou, S. (2023) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c01722 · Cited by 8
Qiu, M., Ye, C., Bao, L., Wu, K., Zhao, Y., Zhao, X., Tang, R., Shang, R., Shang, S., Yuan, C., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.09.023 · Cited by 10
“Enterococcus with SagA expression can produce peptidoglycans, especially muramyl dipeptide (MDP), which induce the activation of host NOD2 and the release of proinflammatory cytokines including tumor necrosis factor (TNF)- a and interleukin (IL)-1 b [25].”
A Review on the Extraction, Structural Characterization, Function, and Applications of Peptidoglycan
Xu, Y., Yi, Z., Xu, M., & Han, Y. (2025) · Macromolecular Rapid Communications · doi:10.1002/marc.202400654 · Cited by 11
Regulatory role of gut microbiota in immunotherapy of hepatocellular carcinoma
Du, J., Guan, Y., & Zhang, E. (2025) · Hepatology International · doi:10.1007/s12072-025-10822-6 · Cited by 10
Unraveling the Role of the Microbiota in Cancer Immunotherapy: A New Frontier
Wang, S., Li, S., Zhang, M., Liu, R., Ye, X., Mao, S., Yu, J., Xie, X., & Tan, W. (2025) · Research · doi:10.34133/research.0744 · Cited by 13
Advanced oral therapies for colorectal cancer via nanomedicine and microbiota modulation
Wang, Y., Chen, C., Xiao, X. H., Kang, Y., He, J., Beloqui, A., & Xu, Y. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115741 · Cited by 10
Li, Q., Goggin, K. E., Seo, S. J., Warawa, J. M., & Egilmez, N. K. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03285-3 · Cited by 11
Bacterial muropeptides promote OXPHOS and suppress mitochondrial stress in mammals
Tian, D., Cui, M., & Han, M. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114067 · Cited by 8
Zheng, C., Sun, L., Zhao, H., Niu, M., Zhang, D., Liu, X., Song, Q., Zhong, W., Wang, B., Zhang, Y., et al. (2024) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2024.100912 · Cited by 16
“…adjuvant components inherited from the parent spores, such as PGN and Mn, which could enhance the immune response through toll-like receptor 2 (TLR2) and cyclic guanosine monophosphate–adenosine monophosphate synthetase stimulator of interferon genes (cGAS-STING) pathways, respectively [37 ,38] .”
BackgroundTargeting microbiome, drug metabolism, and drug delivery in oncology
Sumiyoshi, A., Fujii, H., & Okuma, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114902 · Cited by 9
Microbiome‐driven anticancer therapy: A step forward from natural products
Guan, Y., Wu, D., Wang, H., & Liu, N. (2024) · mLife · doi:10.1002/mlf2.12118 · Cited by 8
Wong, M. K., Boukhaled, G. M., Armstrong, E., Liu, R., Heirali, A., Yee, N., Tsang, J., Spiliopoulou, P., Schneeberger, P. H. H., Wang, B. X., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010681 · Cited by 8
Zhou, B., Xing, Z., Wang, Y., Guan, X., Wang, F., Yin, J., Li, Z., Zhao, Q., Hou, H., & Sang, X. (2025) · Foods · doi:10.3390/foods14132373 · Cited by 8
“Enterococcus , a commensal with probiotic potential (e.g., E. faecium), contributes to immunomodulation and fermented food applications [59].”
A review on the ecological niche and functional properties of enterococci in health promotion
He, Y., Liu, Z., Huang, Y., Qiu, L., Tao, X., & Wei, H. (2025) · Current Research in Food Science · doi:10.1016/j.crfs.2025.101211 · Cited by 9
“Griffin et al. demonstrated that Enterococcus supported immunotherapy of PD-L1 in melanoma by secreting orthologs of NlpC/p60 peptidoglycan hydrolase SagA that generated immune-active muropeptides (Griffin et al., 2021).”
Cao, F., Liu, Z., Liu, S., Liu, Y., Qi, Y. X., Cheng, Y., Wang, Y., & Xu, Y. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1657865 · Cited by 9
Engineered nano-bacteria hybrids for precision cancer immunotherapy
Yu, L., Qiu, Y., Li, R., Xu, Z. C., & Li, R. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102484 · Cited by 10
“This immunomodulatory capacity stems from bacterial molecular signatures, including lipopolysaccharide (LPS) [25], peptidoglycan (PGN) [26], lipoteichoic acid (LTA) [27], and flagella [28], that mediate distinct immunomodulatory effects through PAMPs.”
Hazra, R., Chattopadhyay, S., Mallick, A., Gayen, S., & Roy, S. (2024) · Medical Oncology · doi:10.1007/s12032-024-02416-3 · Cited by 8
“6B) [127, 128].”
Harnessing microbial antigens as cancer antigens: a promising avenue for cancer immunotherapy
Zhang, T., Zhang, X., Chen, J., Zhang, X., & Zhang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1411490 · Cited by 10
Zhong, H., Yu, Y., Abdullah, Zhang, H., Du, J., Sun, J., Chen, L., Feng, F., & Guan, R. (2025) · Food & Function · doi:10.1039/d4fo06100d · Cited by 7
Cholan, P. M., Morris, S., Luo, K., Chen, J., Boland, J. A., McCaughan, G. W., Britton, W. J., & Oehlers, S. H. (2021) · BioFactors · doi:10.1002/biof.1796 · Cited by 8
“stimulatory muropeptides [20], as we have previously demonstrated a conserved function of the 249 zebrafish NOD orthologs it is possible that SagA-mediated production of muropeptides from 250 bacterial peptidoglycan contributes to our hyperlipidaemia-accelerating phenotype.”
BackgroundHilakivi-Clarke, L. A., Verma, V., McDermott, M., Koak, P., & Andrade, F. D. O. (2022) · Frontiers in Microbiomes · doi:10.3389/frmbi.2022.1049688 · Cited by 7
“Besides SCFAs, other potential microbial metabolites to mediate the effects of the gut microbiota on immune cells and responsiveness to ICBs include inosine (Mager et al., 2020) and SagA (Griffin et al., 2021).”
BackgroundInfluentialChemical immunology: Recent advances in tool development and applications
Shi, Y., Bashian, E. E., Hou, Y., & Wu, P. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.02.006 · Cited by 7
Sepulveda, M., Rasic, M., Lei, Y. M., Kwan, M., Chen, L., Chen, Y., Perkins, D. L., & Alegre, M. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.03.020 · Cited by 6
Fuochi, V., Furnari, S., Trovato, L., Calvo, M., & Furneri, P. M. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2351509 · Cited by 7
“Additionally, there is evidence suggesting lower nephrotoxicity compared to gentamicin, indicating potentially greater safety in the treatment of cUTIs [129].”
Wu, B., Quan, C., He, Y., Matsika, J., Huang, J., Liu, B., & Chen, J. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2371543 · Cited by 7
“Enterococci , which possess a distinct NlpC/p60 peptido-glycan hydrolase activity, have the capacity to generate NOD2-active peptides and regulate the therapeutic outcome of ICB [61].”
Distinctive Immune Signatures Driven by Structural Alterations in Desmuramylpeptide NOD2 Agonists
Janež, Š., Guzelj, S., Kocbek, P., de Vlieger, E. A., Slütter, B., & Jakopin, Ž. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01577 · Cited by 7
Microbiota mechanisms in cancer progression and therapy
Zhang, X., Fam, K. T., Dai, T., & Hang, H. C. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.04.005 · Cited by 9
Self-citationMeghani, K. A., Yu, Y., Frydenlund, N., Li, E. Z., Choy, B., Abdulkadir, S. A., & Meeks, J. J. (2025) · European Urology · doi:10.1016/j.eururo.2025.09.4138 · Cited by 7
Advances in Organoid Culture Research
Xie, Z., Wang, L., & Zhang, Y. (2022) · Global Medical Genetics · doi:10.1055/s-0042-1756662 · Cited by 10
Fu, Q., Jiang, J., Li, X., Zhai, Z., Wang, X., Li, C., Chen, Q., Man, C., Du, L., Wang, F., et al. (2023) · Microorganisms · doi:10.3390/microorganisms11020400 · Cited by 6
“As a vital member of the NLR family, NOD2 is a sensor of bacterial peptidoglycan (PGN) recognition [38].”
BackgroundWang, W. “., Pang, W., Yan, S., Zheng, X., Han, Q., Yao, Y., Jin, L., & Zhang, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1165584 · Cited by 9
“It has been suggested that an increased abundance of Enterococcus may promote the antitumor activity of checkpoint inhibitor immunotherapy in melanoma patients (Matson et al., 2018; Griffin et al., 2021).”
BackgroundLi, M., Wu, X. Q., & Lee, T. K. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0476 · Cited by 7
Assessment of probiotic and prebiotic use in gynecologic cancer patients: a systematic review
Chalif, J., Morton, M. A., Haight, P. J., Mehra, Y., O’Malley, D. M., Spakowicz, D. J., & Chambers, L. (2025) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.09.042 · Cited by 6
Cogrossi, L. L., Policastro, A., Zordan, P., Grioni, M., Tosi, A., RIZZO, N., Mattorre, B., Lorenzoni, M., Meregalli, G., Sisti, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65312-y · Cited by 8
“Previous research in mice showed that using anti-biotics to aid probiotic colonization 41,64 didn ’ t prevent the same bacterial strains from being used in humans without antibiotics 65,66 .”
Gut microbiota drives cancer evolution and therapy resistance
Min, S., Zhang, Y., Zhang, H., & Liu, Q. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02564-8 · Cited by 10
Yang, X., Zhang, K., Xia, L., & Li, J. (2026) · iMetaMed · doi:10.1002/imm3.70030 · Cited by 5
Bones and guts – Why the microbiome matters
Contino, K. F., Cook, K. L., & Shiozawa, Y. (2024) · Journal of bone oncology · doi:10.1016/j.jbo.2024.100523 · Cited by 5
“Interestingly, supplementation of Clostridiales strains have been found to improve immunotherapy treatment in murine melanoma and colorectal cancer by inducing CD8 + T-cell infiltration and activation at the tumor site [45].”
BackgroundGut resistome of NSCLC patients treated with immunotherapy
Iwan, E., Grenda, A., Bomba, A., Bielińska, K., Wasyl, D., Kieszko, R., Rolska-Kopińska, A., Chmielewska, I., Krawczyk, P. A., Rybczyńska‐Tkaczyk, K., et al. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1378900 · Cited by 5
Barnet, M. B., Jackson, K., Masle‐Farquhar, E., Russell, A., Burnett, D. L., Chye, A., Jara, C., Faulks, M. L., Mawson, A., Peters, T. J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314258122 · Cited by 8
Advances in anti-tumor research based on bionic micro-nano technology
Gao, J., Yang, P. S., Li, H., Li, N., Liu, X., Cai, K., & Li, J. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104674 · Cited by 5
Gut microbiota and sepsis: mechanisms, clinical correlations, and therapeutic prospects
Yu, J., & Liu, X. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1793041 · Cited by 4
Yang, Z., Liang, L., Li, X., Peng, X., Qian, X., Huang, Z., Wang, X., Hu, Q., & Fu, X. (2026) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2026.117711 · Cited by 7
Microbiome-modulated immunotherapy in oncology: Current applications and future prospects
Liu, Y., Miao, K., & Yang, X. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.01.001 · Cited by 4
Reddy, N., Lau, K., Naman, J., Lu, K. L., McGillivary, E., Salmasi, A., Liss, M. A., & Stewart, T. F. (2026) · OncoImmunology · doi:10.1080/2162402x.2025.2611458 · Cited by 4
Shen, W., Wang, H., Wang, J., Yuan, Y., Luo, Y., Chen, X. G., Li, J., Liu, Y., Yin, Y., Wang, M., et al. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.02.004 · Cited by 6
Microbiome dynamics in immune checkpoint blockade
Kim, C. W., Kim, H.-J., & Lee, H. K. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.04.013 · Cited by 5
Li, J., Tian, X., Hsiang, T., Yang, Y., Shi, C., Wang, H., & Li, W. (2024) · Insects · doi:10.3390/insects15090727 · Cited by 4
“Recent research has found that Enterococcus sp. can trigger immune signaling pathways and modulate infection [62], and Enterococcus peptidoglycan can promote checkpoint inhibitor cancer immunotherapy [63].”
BackgroundPersonalised medicine based on host genetics and microbiota applied to colorectal cancer
González, A., Badiola, I., Fullaondo, A., Rodríguez, J., & Odriozola, A. (2024) · Advances in genetics · doi:10.1016/bs.adgen.2024.08.004 · Cited by 4
The oncobiome; what, so what, now what?
Abbas, M., & Tangney, M. (2025) · Microbiome Research Reports · doi:10.20517/mrr.2024.89 · Cited by 7
Du, Y., Wang, Y., Yang, M., Lin, L., Zhang, J., Huang, Z. Q., Liu, C., Liu, S., Ma, J., Yang, C. J., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202503049 · Cited by 7
Improving immunotherapy response through the use of designer bacteria
Griffin, M. E., & Hang, H. C. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.11.009 · Cited by 4
Self-citationLocal Delivery of Immunomodulatory Antibodies for Gastrointestinal Tumors
Silva-Pilipich, N., Covo-Vergara, Á., & Smerdou, C. (2023) · Cancers · doi:10.3390/cancers15082352 · Cited by 5
Chemoproteomics of microbiota metabolites reveals small-molecule agonists for orphan receptor GPRC5APreprint
Zhao, X., Stein, K. R., Chen, V., Griffin, M. E., & Hang, H. C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.16.472979 · Cited by 4
Self-citationMicrobiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling
Fidelle, M., Lebhar, I., Zitvogel, L., & Kroemer, G. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2224679 · Cited by 4
Microbial-derived immunostimulatory small molecule augments anti-PD-1 therapy in lung cancer
Newsome, R. C., Liu, H., Agbodzi, B., Gharaibeh, R. Z., Zhou, L., & Jobin, C. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102519 · Cited by 5
Liang, Y., Adamson, C., Li, C., Ng, E. W. L., Li, Y., & Yuan, Q. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.01.005 · Cited by 4
Wu, Q., Zhou, Y.-R., Chen, Z.-R., Liu, M.-X., Liu, M.-X., Liu, Y.-F., Li, Z., Zhao, Q.-R., Zhang, Y.-Q., Zhang, H., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105230 · Cited by 5
Gut microbiota and metabolic control of immune checkpoint blockade in cancer
Gladstone, J. L., & Sonnenberg, G. F. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.04.018 · Cited by 4
Ninkov, M., & Vareki, S. M. (2026) · Nature Communications · doi:10.1038/s41467-026-76051-z · Cited by 6
“However, these effects are strain-and context-dependent and should not be inferred from genus-level identity alone 55 .”
Noninvasive Analysis of Peptidoglycan from Living Animals
Ocius, K. L., Kolli, S. H., Ahmad, S. S., Dressler, J. M., Chordia, M. D., Jutras, B. L., Rutkowski, M. R., & Pires, M. M. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00007 · Cited by 3
Photocrosslinking and capture for the analysis of carbohydrate-dependent interactions
Pratt, M. R. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.130077 · Cited by 3
Han, F., Wang, W., Shen, K., Wang, P., Wang, Y., Han, S., Hu, D., Guan, H., & Wu, G. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.169786 · Cited by 4
Mahen, K. K., Markley, L., Bogart, J., Klatka, H., Krishna, V. B., Maytin, E. V., Stark, G. R., & McDonald, C. (2023) · Experimental Dermatology · doi:10.1111/exd.14853 · Cited by 4
Zabolotneva, A. A., Shatova, O. P., Shegai, P. V., & Shestopalov, A. V. (2023) · Oncology Advances · doi:10.14218/ona.2023.00014 · Cited by 3
Human Th17- and IgG3-associated autoimmunity induced by a translocating gut pathobiontPreprint
Gronke, K., Nguyen, M. T., de Souza, N. S., Schumacher, J., Yang, Y., Sonnert, N. D., Leopold, S. R., Martin, A. L., Hallet, R., Richter, K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.29.546430 · Cited by 3
“triggers leading to this immune profile could be conserved among several Enterococcus species similar to certain immunologically active toxins (30) or enzymes (35).”
BackgroundPrasad, R., & Jenq, R. R. (2024) · eLife · doi:10.7554/elife.97277 · Cited by 4
Pan, Y., Jin, L., Huang, Y., Jian, D., Васильевич, К. И., Beluga, M., STALYBKA, A. S., Mou, X., Zhu, Y., Mao, Z., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202424205 · Cited by 2
The role of microbiome in immunotherapy: Insights and perspectives
Ye, M., Ju, H., Ren, G., & Hu, J. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.11.001 · Cited by 4
Liu, X., Gao, J.-B., Li, W.-X., Xu, C., Zhang, Z.-Y., Yang, X., & Ni, M. (2026) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaf321 · Cited by 3
Tumor-associated bacterial effectors: novel frontiers in tumor biology and immunity
Dai, J.-H., Lu, Y.-Q., Feng, S.-Y., Tan, X.-R., Li, L., Zeng, Y.-C., Chen, J., Ma, J., & Liu, N. (2026) · 中国科学通报:英文版 · doi:10.1016/j.scib.2026.04.034 · Cited by 4
Eysha, M., Fouani, M., Munir, M., Black, M., Long, A., Elchouemi, M., Singh, S., & Abid, M. B. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1787954 · Cited by 2
The relationship between gut microbiota and cancer immune response and immunotherapy
Jia, Y., Liu, Y., & Liu, J. Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1833138 · Cited by 2
Microbiome and cancer: mechanistic insights, diagnostic potential, and therapeutic strategies
Kumar, V., Chaudhary, A., Gautam, M., Verma, P., & Singh, M. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1844436 · Cited by 3
“…Burkholderia cepacia ( B. cepacia ), Bifidobacterium pseudolongum ( B. pseudolongum ), Lactobacillus johnsonii ( L. johnsonii ), Olsenella spp., and E. faecium have been shown to promote antitumor immunity in anti-CTLA-4-treated mice (Griffin et al., 2021; Mager et al., 2020; Vétizou et al., 2015).”
InfluentialSasaki, Y. (2024) · American Journal of Cancer Research · doi:10.62347/nhpv3701 · Cited by 3
Lin, H., Zheng, X., Lin, L., Yang, C. J., & Wang, W. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.4c00629 · Cited by 3
Predictive biomarkers for immunotherapy in gastric cancer
Li, S., Liang, H., & Li, G. (2025) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2024.107 · Cited by 4
Onco-biome in pharmacotherapy for lung cancer: a narrative review
Tateishi, A., & Okuma, Y. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-299 · Cited by 2
“presented the molecular mechanisms that influence the host response to immunotherapy (51).”
BackgroundFecal Transplantation in Hematopoietic Transplantation
Peled, J. U., & van den Brink, M. R. M. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01169 · Cited by 2
Li, H., Leaman, A. A., & Zheng, Q. (2025) · Advances in clinical chemistry · doi:10.1016/bs.acc.2025.04.001 · Cited by 4
Microbiota recruitment for brain cancer management
Mehrian‐Shai, R. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001335 · Cited by 2
Fam, K. T., Chodisetti, P. K., Wang, Z., Homer, J. A., Smedley, C. J., Kitamura, S., Silva, B., Xiong, Y., Hansel-Harris, A., Holcomb, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74057-1 · Cited by 2
“…have shown that SagA expression in E. faecium and probiotic bacterial species can promote intestinal immunity 14,15 and cancer immunotherapy in vivo 17 , the VREfm Δ sagA mutant strain is not less pathogenic in this mouse peritonitis infection model, but is more susceptible to vancomycin in vivo…”
InfluentialSelf-citationContrasting outcomes of inherited NOD2 loss-of-function variants on immunotherapy response in cancer
Bousdar, N., Pérez-Ruiz, E., Barragán, I., Benítez, J. C., Rueda‐Domínguez, A., & Oliver, J. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2525911122 · Cited by 2
“Furthermore, mechanistic evidence suggests that the influence of NOD2 on immunotherapy outcomes may be modulated by host– microbiome interactions ( 5 ).”
Harnessing pyroptosis to restrain melanoma through aripiprazole
Chang, Y.-T., Lin, I.-H., Shieh, J., Lan, T., Syu, J., Huang, S. R., & Hou, P. (2026) · APOPTOSIS · doi:10.1007/s10495-025-02223-9 · Cited by 1
Song, D. H., Lee, Y.-R., Yu, S. M., Lee, S. Y., Kim, S.-H., & An, J. H. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.108292 · Cited by 1
Zheng, L., Huang, J., Ni, H., Kuang, X., Liao, J., Qu, Z., Liu, H., Huang, C., Yu, L., Dai, L., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.03.013 · Cited by 1
Yamazaki, T., Minami, A., Kitagawa, K., Yanase, S., Ueki, H., & Shirakawa, T. (2026) · BMC Immunology · doi:10.1186/s12865-026-00827-7 · Cited by 1
“…metabolites and/or cell wall-derived ligands (e.g., peptidoglycan-derived muropeptides and lipoteichoic acid), that engage host pattern-recognition pathways such as NOD2 and TLR2 [19, 21, 22] and thereby contribute to dendritic cell activation and the observed synergy with anti-CTLA-4 therapy.”
InfluentialMicrobiota as a modulator of drug response: targeting microbial–drug crosstalk in cancer therapy
Zhao, T., Liu, M., Qiu, L. X., Zhang, H., Zhang, N., Liu, Z., Xia, Z., Luo, P., Huang, J., & Cheng, Q. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2651930 · Cited by 1
Bukovac, J., Husain, M., Sapper, T. N., O’Dell, A., Bittoni, M. A., Gastier, H., Chebbi, A., Hockenhull, V., Dohar, Z., Moon, J., et al. (2026) · Nutrition and Cancer · doi:10.1080/01635581.2026.2658807 · Cited by 1
Xiao, Z., Xu, H., Ma, N., Lei, L., Cong, C., Sun, N., Wang, G., Chen, X., Ren, K., & Qiao, H. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2531588123 · Cited by 2
Jeon, K., Kim, U., Ji, C.-H., Kamaraj, M., Laird, N. Z., Wang, Z., Yu, H., Ermis, M., Sullan, R. M. A., Shen, X., et al. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103330 · Cited by 1
Microbiome–Driven Carcinogenesis and Circulating Microbial Signals in Genitourinary Cancers
Kawashima, A., Jingushi, K., Saito, T., Uemura, T., Yamamoto, A., Sassi, N., Horitani, H., Inoguchi, S., Horibe, Y., Ishizuya, Y., et al. (2026) · Cancer Science · doi:10.1111/cas.70448 · Cited by 1
Zhou, P., He, Y., Qu, H., Zhou, Y., & Pan, H. H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1866422 · Cited by 3
Alanazi, Y. N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1883259 · Cited by 1
Fang, X., Yuan, S., & Mai, W. (2026) · Immunity Inflammation and Disease · doi:10.1002/iid3.70492 · Cited by 2
Wang, Y., Fan, C., Varatharajalu, K., Satila, M., Cruz, C. C., Sun, B., Lermi, N. O., Hayase, T., Thomas, A., Szymonowicz, K., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103044 · Cited by 1
“45 While our study was not set-up to answer whether FMT could improve cancer outcomes, this should be a focus of larger studies in the future.”
Pei, X., Zhao, J., Luo, R. K., Da, L., Li, E., Zhu, H., Li, Y., Luo, Y., Tian, K., Wang, Z., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1407312 · Cited by 1
Nanomedicine-Driven Modulation of the Microbiota for Cancer Therapy
Yan, H., Li, Z., Iqbal, A. Z., Cai, J., Zhao, Y., & Li, C. (2025) · ACS Applied Nano Materials · doi:10.1021/acsanm.5c01345 · Cited by 1
Kwan, J. M. C., Feng, S., Ng, E. W. L., & Qiao, Y. (2025) · RSC Chemical Biology · doi:10.1039/d5cb00086f · Cited by 1
Metadata
- Authors
- Griffin, M. E., Espinosa, J., Becker, J. L., Luo, J.-D., Carroll, T. S., Jha, J. K., Fanger, G. R., & Hang, H. C.
- Affiliations
- Scripps Research Institute (US)
- Rockefeller University (US)
- Rise Therapeutics, 1405 Research Blvd. Suite 220, Rockville, MD 20850, USA.
- Corresponding author
- Hang, Howard C.
- ORCID
- Venue
- Science
- Published
- 2021-08-27
- Volume
- 373
- Issue
- 6558
- Pages
- 1040-1046
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9503018
- OpenAlex
- W3194929095
- Cited by
- 366
- References
- 75
- Citations by year
- 2026: 69 · 2025: 71 · 2024: 83 · 2023: 80 · 2022: 52 · 2021: 10
- FWCI
- 20.67
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Science (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (1R01CA245292-01, A1070084)
- Melanoma Research Foundation (Career Development Award)
- ASCRS Research Foundation (HCFR-19-03-02)
- Hope Funds for Cancer Research (HCFR-19-03-02)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- Enterococcus, sagas, peptidoglycan remodeling, cancer immunotherapy, PD-L1 blockade, gut microbiota, muramyl peptides, NOD2 signaling, innate immunity, bacterial cell wall degradation
- MeSH terms
- Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Animals, Bacterial Proteins, Immunotherapy, Melanoma, Experimental, Mice, Inbred C57BL, N-Acetylmuramoyl-L-alanine Amidase, Peptide Fragments, Peptidoglycan, Enterococcus faecalis, Signal Transduction, Enterococcus, Enterococcus faecium, Probiotics, Mice, Nod2 Signaling Adaptor Protein, Bacterial Load, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.